{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-23-000015","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.498816+00:00","generated_at":"2026-06-15T23:47:41.166664+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regeneron Q1 revenue up 7% to $3.16B; GAAP EPS $7.17; non-GAAP $10.09","bullets":["Q1 total revenue $3.162B (+7% YoY); GAAP net income $818M (-16%); non-GAAP net income $1.168B (-11%).","EYLEA U.S. net sales $1.43B (-6% YoY); Dupixent global net sales $2.49B (+37%, recorded by Sanofi).","Aflibercept 8 mg BLA accepted for FDA priority review; target action date June 27, 2023 for wet AMD and DME.","Dupixent Phase 3 COPD trial met endpoints: 30% reduction in exacerbations; first biologic to show benefit in COPD.","Full-year 2023 guidance: GAAP R&D raised to $4.225-4.465B; GAAP SG&A raised to $2.49-2.68B; gross margin lowered to 87-89%."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-23-000015","json":"https://secwatch.observer/filing/0001804220-23-000015.json","markdown":"https://secwatch.observer/filing/0001804220-23-000015.md","text":"https://secwatch.observer/filing/0001804220-23-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000015/0001804220-23-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000015/regn-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T23:47:41.166664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7085d3e07a16602f30c4798ce6cc0d7b569c5ea7","claim":"REGENERON PHARMACEUTICALS, INC. reported financial results for the first quarter of 2023.","evidence_excerpt":"On May 4, 2023, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000015/0001804220-23-000015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}